Biotech Values

[oc631]

IMO it reinforces the idea viraemia load at time of treatment more important than days in general.

It's possible and I never discounted the theory. However you are making a subgroup analysis of three primates which could vary widely in human testing. The primate with the early onset of viraemia (secondary?) may have been an immunocompromised outlier. Extended timelines allows for identification of subjects, through the onset of symptoms, in the real world setting.